Aller au contenu principal
Accès ouvert déclaré 2026 article

Ferroptosis at the tumor–immune interface: seeking a middle ground between tumor eradication and T-cell fitness

0Citations signalées — pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Background Ferroptosis is an iron-dependent form of regulated cell death, which is manifested by the lethal accumulation of lipid peroxides. While it is considered a promising strategy for the elimination of apoptosis-resistant cancer cells, growing evidence highlights the dual role of ferroptosis within the tumor microenvironment (TME), affecting both cancer and immune cells. Main body This review integrates tumor- and immune-cell ferroptosis within a three-layer framework comprising membrane lipid composition, antioxidant capacity, and microenvironmental pressure. We discuss how these layers interact to establish distinct ferroptosis thresholds across malignant and cytotoxic T-cell compartments. We highlight that cytotoxic CD8 + T cells and chimeric antigen receptor T cells may be particularly vulnerable to ferroptotic stress as a result of activation-induced metabolic reprogramming and the hostile, nutrient-deprived conditions of the TME. Furthermore, we discuss the immunomodulatory consequences of ferroptosis, including immunogenic and immunosuppressive mediators that can either ignite or stifle antitumor immunity. Lastly, we consider potential approaches that may leverage tumor ferroptosis while preserving T-cell function through tumor-directed ferroptosis induction and reinforcement of antioxidant defenses in engineered T cells. Conclusion We propose that the ferroptosis axis may play a role in shaping the tumor–immune interface. Differential modulation of ferroptosis in tumor and immune cells could inform future strategies to address resistance to immune checkpoint blockade and improve the efficacy of adoptive cell therapies, although such approaches remain largely experimental and their clinical benefit has yet to be established.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Ferroptosis at the tumor–immune interface: seeking a middle ground between tumor eradication and T-cell fitness
Date Crossref
04/09/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Ferroptosis and cancer prognosisImmune cells in cancerCancer Immunotherapy and Biomarkers

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.